A gene that mediates the scale of the hippocampus in both preclinical and human brains is closely associated with the pathology of a group of neurodegenerative diseases, the University of Manchester announced yesterday.

Using 3D brain SPECT scans to guide treatment of psychiatric disorders improved health outcomes and cognitive performance, according to a study published in advance of the Winter 2014 issue of the Journal of Neuropsychiatry and Clinical Neurosciences.

A new guidance document released by the FDA on Monday provides the means to accelerate the process for approving neoadjuvant therapeutic drugs for early-stage, high-risk breast cancer.

Ohio State University announced today that it has completed construction and development on a $13 million molecular imaging research center called Translational Research Center for Molecular Imaging Pharmaceuticals at the Columbus-based Wright Center of Innovation in Biomedical Imaging.

Key scientists behind the development of a prototype optical microscope have garnered the 2014 Nobel Prize in chemistry due to the technology’s ability to surpass all previous limits of optical imaging, the National Institutes of Health (NIH) announced today.

Almost 50 percent of devices and 40 percent of medications administered in the U.S. are produced outside its borders. Around 80 percent of the producers of active pharmaceutical ingredients are internationally based and the speed of global research and commerce is swiftly changing. Clearly, the regulatory framework needs to keep up. With that in mind, the FDA is setting new priorities for the coming years. An official document has been drawn up by the FDA to that effect.

Patients less than 40 years of age originally diagnosed with one of the first three stages of breast cancer underwent a change in clinical staging as a result of PET/CT scanning, according to a study announced Oct. 1 by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

A brain scanner based on differential near-infrared (NIR) energy is getting a healthy push forward with a $3.7 million, four-year contract with the U.S. Marine Corps and Navy for the development of diagnostic imaging for traumatic brain injury and hematoma, makers InfraScan announced Oct. 1.